For research use only. Not for therapeutic Use.
Pemigatinib（Cat No.:I019830）is a selective fibroblast growth factor receptor (FGFR) inhibitor used in the treatment of certain cancers, particularly cholangiocarcinoma with FGFR2 fusions or rearrangements. By targeting FGFR signaling, which drives tumor growth and survival in these cancer types, pemigatinib disrupts the proliferation of malignant cells. It has demonstrated efficacy in patients with advanced or unresectable cholangiocarcinoma, offering a targeted therapy option for individuals with FGFR2 genetic alterations. Pemigatinib represents a significant advancement in precision oncology, improving outcomes in a subset of patients with limited treatment options.
| Catalog Number | I019830 |
| CAS Number | 1513857-77-6 |
| Synonyms | 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one |
| Molecular Formula | C24H27F2N5O4 |
| Purity | 98% |
| Target | FGFR |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | FGFR1:0.4 nM (IC50) |
| IUPAC Name | 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one |
| InChI | InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28) |
| InChIKey | HCDMJFOHIXMBOV-UHFFFAOYSA-N |
| SMILES | CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5 |
| Reference | [1]. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. [2]. Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. [3]. Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). |
